The ubiquitin system, disease, and drug discovery

被引:142
作者
Petroski, Matthew D. [1 ,2 ]
机构
[1] Rigel Pharmaceut Inc, San Francisco, CA 94080 USA
[2] Burnham Inst Med Res, Signal Transduct Program, La Jolla, CA 92037 USA
来源
BMC BIOCHEMISTRY | 2008年 / 9卷
关键词
D O I
10.1186/1471-2091-9-S1-S7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The ubiquitin system of protein modification has emerged as a crucial mechanism involved in the regulation of a wide array of cellular processes. As our knowledge of the pathways in this system has grown, so have the ties between the protein ubiquitin and human disease. The power of the ubiquitin system for therapeutic benefit blossomed with the approval of the proteasome inhibitor Velcade in 2003 by the FDA. Current drug discovery activities in the ubiquitin system seek to (i) expand the development of new proteasome inhibitors with distinct mechanisms of action and improved bioavailability, and (ii) validate new targets. This review summarizes our current understanding of the role of the ubiquitin system in various human diseases ranging from cancer, viral infection and neurodegenerative disorders to muscle wasting, diabetes and inflammation. I provide an introduction to the ubiquitin system, highlight some emerging relationships between the ubiquitin system and disease, and discuss current and future efforts to harness aspects of this potentially powerful system for improving human health. Publication history: Republished from Current BioData's Targeted Proteins database (TPdb; http://www.targetedproteinsdb.com).
引用
收藏
页数:15
相关论文
共 256 条
[1]   The human immunodeficiency virus type 1 accessory protein Vpu induces apoptosis by suppressing the nuclear factor κB-dependent expression of antiapoptotic factors [J].
Akari, H ;
Bour, S ;
Kao, S ;
Adachi, A ;
Strebel, K .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 194 (09) :1299-1311
[2]   STIMULATION-DEPENDENT I-KAPPA-B-ALPHA PHOSPHORYLATION MARKS THE NF-KAPPA-B INHIBITOR FOR DEGRADATION VIA THE UBIQUITIN-PROTEASOME PATHWAY [J].
ALKALAY, I ;
YARON, A ;
HATZUBAI, A ;
ORIAN, A ;
CIECHANOVER, A ;
BEN-NERIAH, Y .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (23) :10599-10603
[3]   Degradation of the Epstein-Barr virus latent membrane protein 1 (LMP1) by the ubiquitin-proteasome pathway - Targeting via ubiquitination of the N-terminal residue [J].
Aviel, S ;
Winberg, G ;
Massucci, M ;
Ciechanover, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (31) :23491-23499
[4]   SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box [J].
Bai, C ;
Sen, P ;
Hofmann, K ;
Ma, L ;
Goebl, M ;
Harper, JW ;
Elledge, SJ .
CELL, 1996, 86 (02) :263-274
[5]  
BAICHWAL VR, 1988, ONCOGENE, V2, P461
[6]   HPV E6, E6AP and cervical cancer [J].
Beaudenon, Sylvie ;
Huibregtse, Jon M. .
BMC BIOCHEMISTRY, 2008, 9
[7]   Involvement of the βTrCP in the ubiquitination and stability of the HIV-1 Vpu protein [J].
Belaidouni, Nadia ;
Marchal, Christelle ;
Benarous, Richard ;
Besnard-Guerin, Corinne .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 357 (03) :688-693
[8]   The tumor suppressor protein p16INK4a and the human papillomavirus oncoprotein-58 E7 are naturally occurring lysine-less proteins that are degraded by the ubiquitin system -: Direct evidence for ubiquitination at the N-terminal residue [J].
Ben-Saadon, R ;
Fajerman, I ;
Ziv, T ;
Hellman, U ;
Schwartz, AL ;
Ciechanover, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (40) :41414-41421
[9]   The polycomb protein Ring1B generates self atypical mixed ubiquitin chains required for its in vitro histone H2A ligase activity [J].
Ben-Saadon, Ronen ;
Zaaroor, Daphna ;
Ziv, Tamar ;
Ciechanover, Aaron .
MOLECULAR CELL, 2006, 24 (05) :701-711
[10]   HIV-1 Vpu sequesters β-transducin repeat-containing protein (βTrCP) in the cytoplasm and provokes the accumulation of β-catenin and other SCFβTrCP substrates [J].
Besnard-Guerin, C ;
Belaïdouni, N ;
Lassot, I ;
Segeral, E ;
Jobart, A ;
Marchal, C ;
Benarous, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (01) :788-795